Literature DB >> 9205945

The Fas counterattack: a molecular mechanism of tumor immune privilege.

J O'Connell1, M W Bennett, G C O'Sullivan, J K Collins, F Shanahan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9205945      PMCID： PMC2230082     

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


× No keyword cloud information.
  72 in total

1.  Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes.

Authors:  S Yonehara; Y Nishimura; S Kishil; M Yonehara; K Takazawa; T Tamatani; A Ishii
Journal:  Int Immunol       Date:  1994-12       Impact factor: 4.823

2.  FAP-1: a protein tyrosine phosphatase that associates with Fas.

Authors:  T Sato; S Irie; S Kitada; J C Reed
Journal:  Science       Date:  1995-04-21       Impact factor: 47.728

3.  Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression.

Authors:  G S Korbutt; J F Elliott; R V Rajotte
Journal:  Diabetes       Date:  1997-02       Impact factor: 9.461

4.  CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.

Authors:  P M Stuart; T S Griffith; N Usui; J Pepose; X Yu; T A Ferguson
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

5.  Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

Authors:  S Strand; W J Hofmann; H Hug; M Müller; G Otto; D Strand; S M Mariani; W Stremmel; P H Krammer; P R Galle
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

6.  Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line.

Authors:  T Tamura; S Ueda; M Yoshida; M Matsuzaki; H Mohri; T Okubo
Journal:  Biochem Biophys Res Commun       Date:  1996-12-04       Impact factor: 3.575

7.  Expression of the Fas ligand in cells of T cell lineage.

Authors:  T Suda; T Okazaki; Y Naito; T Yokota; N Arai; S Ozaki; K Nakao; S Nagata
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

8.  Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis.

Authors:  R C Bargou; P T Daniel; M Y Mapara; K Bommert; C Wagener; B Kallinich; H D Royer; B Dörken
Journal:  Int J Cancer       Date:  1995-03-16       Impact factor: 7.396

Review 9.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

10.  Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias.

Authors:  E Knipping; K M Debatin; K Stricker; B Heilig; A Eder; P H Krammer
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113
View more
  12 in total

1.  Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.

Authors:  Wei Zhang; Er-Xun Ding; Qiang Wang; Da-Qiao Zhu; Jin He; Yu-Li Li; Yuan-He Wang
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

3.  Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin.

Authors:  G Pan; S M Vickers; A Pickens; J O Phillips; W Ying; J A Thompson; G P Siegal; J M McDonald
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

4.  Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J O'Callaghan; J K Collins; F Shanahan
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

5.  Proinflammatory consequences of transgenic fas ligand expression in the heart.

Authors:  D P Nelson; E Setser; D G Hall; S M Schwartz; T Hewitt; R Klevitsky; H Osinska; D Bellgrau; R C Duke; J Robbins
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.

Authors:  Qian Li; Jie Peng; Xin-Hua Li; Ting Liu; Qing-Chun Liang; Gui-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

7.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

8.  Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.

Authors:  Yin Li; Da-Fu Xu; Dong Jiang; Jun Zhao; Jin-Feng Ge; Shi-Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  The distribution and intracellular location of Fas and Fas Ligand following gastric carcinogenesis: Fas Ligand expressing gastric carcinoma cells can inhibit local immune response.

Authors:  Huanran Liu; Hideyuki Ubukata; Takanobu Tabuchi; Takeshi Nakachi; Hiroyuki Nagata; Jiro Shimazaki; Gyou Motohashi; Satoru Konishi; Motoi Nishimura; Tetsuro Satani; JianWei Hong; Ichiro Nakada; Abbi R Saniabadi; Takafumi Tabuchi
Journal:  Mol Cell Biochem       Date:  2009-05-21       Impact factor: 3.396

Review 10.  Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.

Authors:  Michael R Verneris; Jeanette Baker; Matthias Edinger; Robert S Negrin
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.